Drugs / ARO-033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07662096 | Jun 2026 → Jul 2027 expected | — | Arrowhead Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662096 ↗ |
| Route | Subcutaneous | “ARO-033 will be administered as a subcutaneous (SC) injection per schedule specified in the arm description.” NCT07662096 ↗ |